Teresa Heitsenrether was appointed as Director at CVS HEALTH Corp.
“On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, effective November 18, 2026.”
CVS HEALTH Corp — fact timeline
Source-grounded facts extracted from CVS HEALTH Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Larry M. Robbins resigned as Director at CVS HEALTH Corp.
“On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately.”
CVS HEALTH Corp shareholders rejected Stockholder proposal for reducing the threshold for the right to act by written consent at the 2026-05-14 meeting.
“Stockholder proposal for reducing the threshold for the Company’s stockholder right to act by written consent, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 417,969,177 617,361,014 3,388,283 104,083,932”
CVS HEALTH Corp shareholders approved Approval of the Company's 2026 Incentive Compensation Plan at the 2026-05-14 meeting.
“Company proposal to approve the Company’s 2026 Incentive Compensation Plan, as set forth in the Company's Proxy Statement, was approved by the following vote: 1,006,709,390 28,851,289 3,157,795 104,083,932”
CVS HEALTH Corp shareholders approved Advisory approval of named executive officer compensation at the 2026-05-14 meeting.
“Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers, as set forth in the Company’s Proxy Statement, was approved by the following vote: 976,252,194 59,088,923 3,377,357 104,083,932”
CVS HEALTH Corp shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-05-14 meeting.
“Company proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026, as set forth in the Company’s Proxy Statement, was approved by the following vote: 1,117,411,640 24,102,167 1,288,599 None”
CVS HEALTH Corp shareholders approved Election of 13 nominees for one-year terms at the 2026-05-14 meeting.
“The election, for one-year terms, of persons nominated for election as directors of the Company, as set forth in the Company’s Proxy Statement, was approved by the following votes: Fernando Aguirre 1,022,555,114 14,973,034 1,190,326 104,083,932 Jeffrey R. Balser, M.D., Ph.D. 1,027,705,454 9,787,711 1,225,309 104,083,932 C. David Brown II 963,381,905 74,082,639 1,253,930 104,083,932 Alecia A. DeCoudreaux 996,234,731 41,326,102 1,157,641 104,083,932 Anne M. Finucane 1,010,527,586 27,032,194 1,158,694 104,083,932 John E. Gallina 1,024,886,453 12,566,628 1,265,393 104,083,932 J. David Joyner 968,110,706 66,554,762 4,053,006 104,083,932 J. Scott Kirby 995,832,249 41,667,652 1,218,573 104,083,932 Michael F. Mahoney 940,279,615 96,450,126 1,988,733 104,083,932 Leslie V. Norwalk 1,021,952,646 15,580,839 1,184,989 104,083,932 Larry M. Robbins 1,026,332,859 11,150,192 1,235,423 104,083,932 Guy P. Sansone 995,433,957 42,056,031 1,228,486 104,083,932 Douglas H. Shulman 1,020,665,806 16,793,215 1,2”
CVS HEALTH Corp reported the three months ended March 31, 2026 results: revenue $100.4 billion, net income $2,957, EPS $2.30. Guidance raised.
“CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE • First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year • First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57”
Thomas F. Cowhey changed role as Executive Vice President and Chief Financial Officer at CVS HEALTH Corp.
“On April 7, 2025, the Board of Directors of the Company also determined that Thomas F. Cowhey, currently the Executive Vice President and Chief Financial Officer of CVS Health, will cease to serve as Executive Vice President and Chief Financial Officer of CVS Health as of the Effective Date.”
Brian O. Newman was appointed as Executive Vice President and Chief Financial Officer at CVS HEALTH Corp.
“On April 7, 2025, the Board of Directors of CVS Health Corporation (the “Company” or “CVS Health”) appointed Brian O. Newman to serve as Executive Vice President and Chief Financial Officer of CVS Health, effective May 12, 2025 (the “Effective Date”).”
Doug Shulman was appointed as Director at CVS HEALTH Corp.
“On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.”
Guy Sansone was appointed as Director at CVS HEALTH Corp.
“On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.”
Larry Robbins was appointed as Director at CVS HEALTH Corp.
“On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.”
Leslie Norwalk was appointed as Director at CVS HEALTH Corp.
“On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.”
Prem S. Shah was appointed as Executive Vice President and Group President at CVS HEALTH Corp.
“On November 6, 2024, CVS Health Corporation (the “ Company ”) appointed Prem S. Shah as Executive Vice President and Group President, a newly created position within the Company.”
Roger N. Farah was appointed as Executive Chairman of the Board at CVS HEALTH Corp.
“Effective October 17, 2024, the Board has also appointed current Chairman Roger N. Farah as Executive Chairman of the Board.”
Karen S. Lynch resigned as President and Chief Executive Officer at CVS HEALTH Corp.
“Karen S. Lynch ceased to serve as President and Chief Executive Officer of the Company and resigned as a member of the Board on the same day.”
J. David Joyner was appointed as President and Chief Executive Officer at CVS HEALTH Corp.
“the Board of Directors (the “ Board ”) of the Company appointed J. David Joyner as President and Chief Executive Officer of the Company, effective as of October 17, 2024.”
CVS HEALTH Corp reported full-year 2024 results: EPS Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06. Guidance lowered.
“Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06”
CVS HEALTH Corp reported the three months ended March 31, 2024 results: revenue $88,437, EPS $0.88.
“results for the three months ended March 31, 2024. Financial Results Summary Three Months Ended March 31, In millions, except per share amounts 2024 2023 Change Total revenues $ 88,437 $ 85,278 $ 3,159 Operating income 2,271 3,446 (1,175) Adjusted operating income (1) 2,957 4,370 (1,413) Diluted earnings per share $ 0.88 $ 1.65 $ (0.77) Adjusted EPS (2) $ 1.31 $”
CVS HEALTH Corp reported three months and year ended December 31, 2023 results: revenue $93.8 billion, EPS GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12. Guidance lowered.
“(NYSE: CVS) today announced operating results for the three months and year ended December 31, 2023. FOURTH QUARTER HIGHLIGHTS KEY FINANCIAL DATA • Total revenues increased to $93.8 billion, up 11.9% compared to prior year • GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12 FULL-YEAR HIGHLIGHTS • Total revenues increased to $357.8 billion, up 10.9% compared to”
Shawn M. Guertin departed as Executive Vice President, Chief Financial Officer and President of Health Services at CVS HEALTH Corp.
“On January 5, 2024, CVS Health also announced that Shawn M. Guertin, who, as previously disclosed, was on a personal leave of absence since October 13, 2023, will step down from his role as CVS Health’s Executive Vice President, Chief Financial Officer and President of Health Services due to family health reasons, effective immediately.”
Thomas F. Cowhey was appointed as Executive Vice President and Chief Financial Officer at CVS HEALTH Corp.
“The Board of Directors (the “Board”) of CVS Health appointed Thomas F. Cowhey to serve as CVS Health’s Executive Vice President and Chief Financial Officer, effective January 5, 2024.”
CVS HEALTH Corp reported three months ended September 30, 2023 results: revenue $89.8 billion, EPS GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21. Guidance reaffirmed.
“(NYSE: CVS) today announced operating results for the three months ended September 30, 2023. Third quarter highlights Key financial data • Total revenues increased to $89.8 billion, up 10.6% compared to prior year • GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21 Year-to-date highlights • Total revenues increased to $264.0 billion, up 10.6% compared to”
Thomas F. Cowhey was appointed as Interim Chief Financial Officer at CVS HEALTH Corp.
“Appointment of Interim Chief Financial Officer In connection with Mr. Guertin’s leave, the Company’s Board of Directors appointed Thomas F. Cowhey, Senior Vice President, Corporate Finance, to serve as the Company’s Interim Chief Financial Officer, effective October 13, 2023.”
Shawn M. Guertin departed as Executive Vice President and Chief Financial Officer at CVS HEALTH Corp.
“Effective October 13, 2023, Shawn M. Guertin, the Executive Vice President and Chief Financial Officer of CVS Health Corporation (“CVS Health,” the “Company,” “we” or “our”), has begun a personal leave of absence for unforeseen family medical reasons.”
Michael F. Mahoney was elected as Director at CVS HEALTH Corp.
“On September 20, 2023, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected Michael F. Mahoney to serve on the Board, effective November 1, 2023.”
CVS HEALTH Corp reported 2023 Full-year results: EPS $6.53 to $6.75. Guidance lowered.
“Revised GAAP diluted EPS guidance range to $6.53 to $6.75 from $6.90 to $7.12”
CVS HEALTH Corp reported the three months ended June 30, 2023 results: revenue $88,921, EPS $1.48. Guidance lowered.
“Adjusted EPS of $4.41 • Generated cash flow from operations of $13.3 billion Three Months Ended June 30, In millions, except per share amounts 2023 2022 Change Total revenues $ 88,921 $ 80,636 $ 8,285 Operating income 3,234 4,669 (1,435) Adjusted operating income (1) 4,481 5,002 (521) Diluted earnings per share $ 1.48 $ 2.29 $ (0.81) Adjusted EPS (2) $ 2.21 $”
J. Scott Kirby was elected as Director at CVS HEALTH Corp.
“elected J. Scott Kirby to serve on the Board, effective October 1, 2023.”
CVS HEALTH Corp shareholders rejected Stockholder proposal to prevent directors from simultaneously sitting on boards of other companies at the 2023-05-18 meeting.
“9. Stockholder proposal to prevent Company directors from simultaneously sitting on the boards of directors of any other company, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 12,060,476 918,626,020 4,913,326 158,712,081”
CVS HEALTH Corp shareholders rejected Stockholder proposal requesting a report on a 'worker rights assessment' at the 2023-05-18 meeting.
“8. Stockholder proposal requesting a report on a “worker rights assessment”, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 241,981,808 676,428,357 17,189,657 158,712,081”
CVS HEALTH Corp shareholders rejected Stockholder proposal regarding 'fair elections' and requiring stockholder approval of certain by-law amendments at the 2023-05-18 meeting.
“7. Stockholder proposal regarding “fair elections” and requiring stockholder approval of certain types of by-law amendments, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 171,929,804 755,940,917 7,729,101 158,712,081”
CVS HEALTH Corp shareholders rejected Stockholder proposal for reducing ownership threshold to request a special stockholder meeting at the 2023-05-18 meeting.
“6. Stockholder proposal for reducing the Company’s ownership threshold to request a special stockholder meeting, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 380,646,548 551,246,853 3,706,421 158,712,081”
CVS HEALTH Corp shareholders rejected Stockholder proposal requesting paid sick leave for all employees at the 2023-05-18 meeting.
“5. Stockholder proposal requesting paid sick leave for all employees, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 239,883,042 675,362,283 20,354,497 158,712,081”
CVS HEALTH Corp shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-18 meeting.
“4. Company proposal seeking a recommendation, on an advisory basis, regarding the frequency of future stockholder votes on executive compensation resulted in a recommendation of every one (1) year, with the following votes recorded: One year: 911,385,062 Two years: 2,416,638 Three years: 18,824,696 Abstain: 2,973,426”
CVS HEALTH Corp shareholders approved Advisory vote to approve executive compensation at the 2023-05-18 meeting.
“3. Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers, as set forth in the Company’s Proxy Statement, was approved by the following vote: 745,115,461 185,740,147 4,744,214 158,712,081”
CVS HEALTH Corp shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-05-18 meeting.
“2. Company proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023, as set forth in the Company’s Proxy Statement, was approved by the following vote: 1,066,204,214 25,251,007 2,856,682 None”
CVS HEALTH Corp shareholders approved Election of 11 nominees for director for a one-year term at the 2023-05-18 meeting.
“Item 5.07 Submission of Matters to a Vote of Security Holders. The following are the voting results on each matter submitted to the stockholders of CVS Health Corporation (the “Company”) at the Annual Meeting of Stockholders held on May 18, 2023 (the “Annual Meeting”). The proposals below are described in detail in the proxy statement filed by the Company on April 7, 2023 (the “Proxy Statement”). There were present at the Annual Meeting, in person or by valid proxy, the holders of 1,094,311,903 shares of the Company’s common stock, constituting a quorum. At the Annual Meeting, the 11 nominees for director were elected to the Company’s Board of Directors for a term of one year (Item 1).”
CVS HEALTH Corp reported three months ended March 31, 2023 results: revenue $85,278. Guidance lowered.
“Adjusted EPS of $2.20 • Generated cash flow from operations of $7.4 billion Three Months Ended March 31, In millions, except per share amounts 2023 2022 Change Total revenues $ 85,278 $ 76,826 $ 8,452 Operating income 3,446 3,545 (99) Adjusted operating income (1) 4,370 4,607 (237) Diluted earnings per share $ 1.65 $ 1.77 $ (0.12) Adjusted EPS (2) $ 2.20 $ 2.30”
CVS HEALTH Corp incurred term loan of $5.0 billion with Barclays Bank PLC at term SOFR or the base rate, plus, in each case, an applicable margin maturing April 30, 2024.
“On May 1, 2023, CVS Health Corporation, a Delaware corporation (“CVS Health”) entered into a 364-Day Term Loan Agreement (the “Term Loan Agreement”) with the lenders party thereto and Barclays Bank PLC, as administrative agent. The Term Loan Agreement provides for total term loan commitments in an aggregate principal amount of $5.0 billion.”
CVS HEALTH Corp entered into Term Loan Agreement valued at $5.0 billion.
“The Merger was financed in part with borrowings of $5.0 billion under the Term Loan Agreement, described above under Item 1.01 of this Current Report.”
CVS HEALTH Corp entered into Agreement and Plan of Merger with Oak Street Health, Inc. (effective 2023-02-07).
“On February 7, 2023, CVS Pharmacy, Inc. (“Parent”), a Rhode Island corporation and wholly owned direct subsidiary of CVS Health Corporation (“CVS Health”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Oak Street Health, Inc., a Delaware corporation (“Oak Street Health”), Halo Merger Sub Corp., a Delaware corporation and wholly owned direct subsidiary of Parent (“Merger Sub”), and, for the limited purposes set forth therein, CVS Health, pursuant to which Merger Sub will merge with and into Oak Street Health and Oak Street Health will be the surviving corporation in the Merger and will continue as a wholly owned direct subsidiary of Parent (the “Merger”).”
CVS HEALTH Corp reported financial results for for the three months and year ended December 31, 2022.
“CVS Health Corporation issued a press release announcing results for the three months and full year ended December 31, 2022.”
Alan M. Lotvin departed as Executive Vice President and President, Pharmacy Services at CVS HEALTH Corp.
“On January 18, 2023, Alan M. Lotvin, M.D., Executive Vice President and President, Pharmacy Services, advised CVS Health Corporation of his intention to retire in April 2023.”
CVS HEALTH Corp reported full-year 2023 results: EPS $8.70 to $8.90. Guidance reaffirmed.
“The Company will also reaffirm its projected full-year 2023 Adjusted EPS guidance range of $8.70 to $8.90”
CVS HEALTH Corp reported full-year 2022 results: EPS $8.55 to $8.65. Guidance reaffirmed.
“the Company will disclose that it has reaffirmed its estimated full-year 2022 Adjusted earnings per share ("EPS") guidance range of $8.55 to $8.65”
CVS HEALTH Corp: Amended by-laws to revise Section 1.10 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-17).
“On November 17, 2022, the Board of Directors of CVS Health Corporation (the “Company”) amended, effective immediately, the by-laws (the “By-laws”) of the Company to (a) revise Section 1.10 with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.”
CVS HEALTH Corp reported 2022 (year-to-date) results: revenue $238.6 billion, EPS $1.40. Guidance raised.
“Total revenues increased to $238.6 billion, up 10.7% compared to prior year”
CVS HEALTH Corp reported three months ended September 30, 2022 results: revenue $81.2 billion, EPS $(2.60). Guidance raised.
“Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2022. THIRD QUARTER RESULTS KEY FINANCIAL DATA • Total revenues increased to $81.2 billion, up 10.0% compared to prior year • GAAP loss per share of $(2.60), inclusive of $5.2 billion pre-tax opioid litigation charges and a $2.5 billion pre-tax loss on assets held for”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.